Read the small print
What do the harm reports leave unanswered?
Keep the reassuring-sounding finding and its limits on the same page.
FDA—the Food and Drug Administration—handles US reviews of medicines.
- What the small studies reported
The FDA review checked on 28 September 2026 found no apparent serious adverse events in the small human studies it examined.
An adverse event is an unwanted experience during use of a medical product, rather than proof the product caused it.
- What that leaves unknown
Those studies were brief and small, with limited safety information and unclear monitoring in most cases.
The FDA said there was too little information to describe BPC-157’s risks, including which unwanted effects occur and how often.
What is the FDA worried about?
The FDA describes a risk that BPC-157 given by injection or sprayed into the nose could trigger an immune response, meaning the body reacts against the substance.
None of the studies in that review formally tested this kind of reaction to BPC-157.
The review flags two concerns: BPC-157 forming clumps and unwanted material in the medicine. Both could increase the chance of the body reacting against it.
Ask the doctor to explain what evidence addresses those concerns for the proposed product.
What about pregnancy or other medicines?
Because BPC-157 had no FDA approval at the 28 September 2026 check, it had no FDA-reviewed label explaining effects on pregnancy or other medicines.
Tell the doctor about other medicines, pregnancy questions and health concerns. Ask what is known and what remains unknown for you.